Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
06/2009
06/25/2009US20090162390 Molecular Scaffolds for HIV-1 Immunogens
06/25/2009US20090162385 Compositions for and methods of enhancing the immune response to antigens
06/25/2009US20090162383 Method for designing vaccines against constantly mutating pathogens
06/25/2009US20090162376 Trans-capsular administration of p38 map kinase inhibitors into orthopedic joints
06/25/2009US20090162368 Mechanosensitive mammalian potassium channel activatable by polyunsaturated fatty acids
06/25/2009US20090162367 Nucleotide and protein sequences of Nogo genes and methods based thereon
06/25/2009US20090162365 Novel siRNAS and methods of use thereof
06/25/2009US20090162363 Pedf-r receptor and uses
06/25/2009US20090162361 Method for diagnosing pancreatic cancer
06/25/2009US20090162351 Transdiscal administration of inhibitors of p38 MAP kinase
06/25/2009US20090162349 Method for prevention or treatment of diseases or disorders related to excessive formation of vascular tissue or blood vessels
06/25/2009US20090162347 Methods, compositions, and kits relating to chitinases and chitinase-like molecules and inflammatory disease
06/25/2009US20090162341 For inhibition or reduction of exocytic fusion in a nociceptive sensory afferent cell comprising a Targeting Moiety, a non-cytotoxic protease and a Translocation Domain; pain
06/25/2009US20090162338 Inhibiting metastasis of cancer cells by administering a phosphatidyl inositol 3-kinase inhibitor such as Wortmannin or LY294002 (2-(4-Morpholinyl)-8-phenyl-4H-1-benzopyran-4-one)
06/25/2009US20090162335 Melatonin and immunostimulating substance-based compositions
06/25/2009US20090162333 Pharmaceutical composition comprising apolipoproteins for the treatment of human diseases
06/25/2009US20090162332 Methods and compositions for treating brain diseases
06/25/2009US20090162319 Reverse transcriptase inhibitors
06/25/2009US20090162318 Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors
06/25/2009US20090162314 Magnesium-Containing Polymers for the Treatment of Hyperphosphatemia
06/25/2009US20090162313 High-Molecular Weight Conjugate of Podophyllotoxins
06/25/2009US20090162312 Novel biodegradable biofouling control coating and method of formulation
06/25/2009US20090162311 Agent for Prevention and/or Treatment of Glomerulopathy
06/25/2009US20090162305 Formulations of low oil content comprising diphenylmethane derivatives
06/25/2009US20090162303 Composition containing two polyesters
06/25/2009US20090162301 Antiseptic Compositions
06/25/2009US20090162300 Buccal, polar and non-polar spray containing alprazolam
06/25/2009US20090162299 Caffeine salt complexes and methods for using the same in the prevention or treatment of cancer
06/25/2009US20090162298 Buccal, polar and non-polar spray containing sumatriptan
06/25/2009US20090162297 Buccal, polar and non-polar spray containing ondansetron
06/25/2009US20090162292 Substituted 4--piperidine-1-carboxylic acid esters as a2ar agonists
06/25/2009US20090162289 A tetrapyrollic photosensitizer compound with one pendant CH2CH2CON(CH2CON(CH2COOH)2)2 or N(CH2COOH)2 group, being a chlorin, bacteriochlorin, porphyrin, pyropheophorbide, purpurinimide, or bacteriopurpurinimide; water soluble photosensitizing and imaging compounds; hyperproliferative tissue
06/25/2009US20090162288 Use of modified vaccinia virus strains in combination with a chemotherapeutic agent for use in therapeutic methods
06/25/2009US20090162286 Phosphodiesterase 10 Inhibition as Treatment for Obesity-Related and Metabolic Syndrome-Related Conditions
06/25/2009US20090162285 Anti-inflammatory fusion protein
06/25/2009US20090162283 Diagnostic and remedy for disease caused by amyloid aggregation and/or deposition
06/25/2009US20090162282 Substituted 4--piperidine-1-carboxylic acid esters as a2ar agonists
06/25/2009US20090162281 Radionuclide labeling of Vitamin B12 and Co-enzymes thereof
06/25/2009US20090162279 Oligonucleotide or Its Functional Homologue, a Composition Comprising the Same and a Method of Treating B Cell Neoplasm
06/25/2009DE102008062373A1 Mittel, mit mindestens einem Wirkstoff, der eine Zahnfleischwachstumswirkung aufweist Means, with at least one active ingredient that comprises a gum growth effect
06/25/2009DE102007063671A1 Neue kristalline Diphenylazetidinonhydrate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung New crystalline Diphenylazetidinonhydrate, pharmaceutical compositions containing them and their use
06/25/2009DE102007063210A1 Arzneimittel zur Behandlung von Phantomphänomenen Drugs for treatment of phantom phenomena
06/25/2009DE102007062550A1 Perhydrochinoxalin-Derivate Perhydroquinoxaline derivatives
06/25/2009DE102007061963A1 Pyridazinonderivate Pyridazinone derivatives
06/25/2009DE102007061797A1 Method for gestagen treatment of hyperplastic process in endometrium, comprises selecting individual case-specific preparation, producing cytosolic fraction, detecting progesterone receptor level and measuring extent of specific binding
06/25/2009DE102007061766A1 New 4-(4-cyano-2-thioaryl)-dihydro-pyrimidinone compounds are human neutrophil elastase inhibitor, useful for the treatment or prevention of e.g. pulmonary arterial hypertonia, acute lung injury and diseases of the cardiovascular system
06/25/2009DE102007061764A1 Anellierte Cyanopyridine und ihre Verwendung Fused cyanopyridines and their use
06/25/2009DE102007061763A1 Substituierte azabicyclische Verbindungen und ihre Verwendung Substituted azabicyclic compounds and their use
06/25/2009DE102007061757A1 Substituierte 2-Phenylpyrimidin-5-carbonsäuren und ihre Verwendung Substituted 2-phenyl-pyrimidine-5-carboxylic acids and their use
06/25/2009DE102007061756A1 Substituierte 4-Aminopyrimidin-5-carbonsäuren und ihre Verwendung Substituted 4-aminopyrimidine-5-carboxylic acids and their use
06/25/2009DE102007061630A1 Preparing montelukast sodium, useful e.g. to antagonize leukotriene, comprises reacting sodium alkoxide compound with montelukast acid in organic solvent, where the montelukast acid is obtained by acidifying montelukast cyclohexylamine
06/25/2009DE102007061262A1 Neue Verwendung von Tribendimidin New use of Tribendimidin
06/25/2009DE102007060172A1 New nitrogen substituted heterocyclic compounds are glycogen synthase kinase 3-beta inhibitors useful e.g. to treat and/or prevent hematological disease, preferably leukopenia, and for ex-vivo increase of adult hematopoietic stem cells
06/25/2009CA2747095A1 Optical correction
06/25/2009CA2711961A1 Transcutaneous pharmaceutical compositions containing a steroid hormone
06/25/2009CA2710006A1 Octahydroquinoli zines for antidiabetic treatment
06/25/2009CA2709918A1 Benzopyrans and analogs as rho kinase inhibitors
06/25/2009CA2709905A1 Pharmaceutical composition
06/25/2009CA2709903A1 Pharmaceutical composition
06/25/2009CA2709883A1 Benzimidazoles and analogs as rho kinase inhibitors
06/25/2009CA2709862A1 Sinomenine derivatives and processes for their synthesis
06/25/2009CA2709821A1 5-oxo-3-pyrrolidinecarboxamide derivatives as p2x7 modulators
06/25/2009CA2709816A1 Isothiazolidine 1,1-dioxide and tetrahydro-2h-1,2-thiazine 1,1-dioxide derivatives as p2x7 modulators
06/25/2009CA2709749A1 3-substituted-4-oxo-3,4-dihydro-imidazo[5,1-d][1,2,3,5]-tetrazine-8-carboxylic acid amides and their use
06/25/2009CA2709579A1 Materials and methods for treatment of pathological ocular vascular proliferation
06/25/2009CA2709566A1 Stem-like cells and method for reprogramming adult mammalian somatic cells
06/25/2009CA2709553A1 Compound inducing angiogenesis response in ischaemic tissues
06/25/2009CA2709407A1 Anthelmintic agents and their use
06/25/2009CA2709396A1 Prevention of opportunistic infections in immune-compromised subjects
06/25/2009CA2709274A1 Novel compounds useful in therapeutic and cosmetic methods
06/25/2009CA2709187A1 4-imidazolidinones as kv1.5 potassium channel inhibitors
06/25/2009CA2709186A1 4-imidazolidinones as kv1.5 potassium channel inhibitors
06/25/2009CA2709176A1 Reverse transcriptase inhibitors
06/25/2009CA2709126A1 Pharmaceutically acceptable salts of methyl (3-{ [[3-(6- amino- 2-butoxy-8-oxo-7, 8-dihydro-9h-purin-9-yl) propyl] (3- morpholin-4-ylpropyl) amino] methyl }phenyl) acetate and their use in therapy
06/25/2009CA2709119A1 Preventive or therapeutic agent for inflammatory bowel diseases
06/25/2009CA2709089A1 Macrocyclic oximyl hepatitis c serine protease inhibitors
06/25/2009CA2709081A1 Cyclopropyl amine derivatives
06/25/2009CA2709068A1 Benzofuran anilide histone deacetylase inhibitors
06/25/2009CA2708866A1 Bicyclic heterocyclic derivative
06/25/2009CA2708822A1 Kinesin inhibitors as cancer therapeutics
06/25/2009CA2708791A1 Novel imidazole-substituted arylamides
06/25/2009CA2708786A1 Therapeutic uses of compounds having affinity to the serotonin transporter, serotonin receptors and noradrenalin transporter
06/25/2009CA2708785A1 4-[2,3-difluoro-6-(2-fluoro-4-methyl-phenylsulfanyl)-phenyl]-piperidine
06/25/2009CA2708761A1 Compositions and methods for treating and preventing skeletal muscle deficiencies
06/25/2009CA2708679A1 Medium-chain length fatty acids, salts and triglycerides in combination with gemcitabine for treatment of pancreatic cancer
06/25/2009CA2708654A1 Breast cancer treatment and treatment prediction
06/25/2009CA2708409A1 Process for recovering flunixin from pharmaceutical compositions
06/25/2009CA2708391A1 Ppar-delta ligands and methods of their use
06/25/2009CA2708361A1 Novel imidazo[1,2-a]pyridine and imidazo[1,2-b]pyridazine derivatives
06/25/2009CA2708324A1 Viral polymerase inhibitors
06/25/2009CA2708228A1 Tetrazole-substituted arylamide derivatives and their use as p2x3 and/or p2x2/3 purinergic receptor antagonists
06/25/2009CA2708118A1 Mineralocorticoid receptor modulators
06/25/2009CA2708113A1 Compounds for use in the treatment of cancer
06/25/2009CA2707990A1 Leukotriene b4 inhibitors
06/25/2009CA2707988A1 Novel pyrazole-substituted arylamides
06/25/2009CA2707980A1 Misuse preventative, controlled release formulation
06/25/2009CA2707785A1 Indoles and their therapeutic use
06/25/2009CA2707768A1 Topical compositions comprising non-proteogenic amino acids and methods of treating skin
06/25/2009CA2707615A1 Azolylmethyloxiranes, their use and compositions comprising them
06/25/2009CA2707513A1 Tetrahydrocyclopenta[b]indol-3-yl carboxylic acid derivatives useful in the treatment of autoimmune and inflammatory disorders